prescription control raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
=== Pentomic organization === In 1957, the division implemented the pentomic organization, officially Reorganization of the Airborne Division (ROTAD), to better prepare for tactical nuclear war in Europe. Five battle groups, each with a headquarters and service company, five rifle companies and a mortar battery, replaced the division's three regiments of three battalions each. The division's battle groups were:
Small amounts of organoselenium compounds have been used to modify the catalysts used for the vulcanization for the production of rubber. Selenium is used in some anti-dandruff shampoos in the form of selenium disulfide such as Selsun and Vichy Dereos brands.
Sinecatechins (Veregen) was the first botanical drug approved in the US in 2006; a green tea extract, for genital warts Crofelemer (Mytesi), approved by the FDA in 2012, an extract of "dragon's blood" sap of the Croton lechleri plant, for diarrhea in people with HIV/AIDS Nabiximols (USAN, trade name Sativex) is a specific extract of Cannabis approved as a botanical drug in the United Kingdom as a mouth spray for people with multiple sclerosis, who can use it to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms; it was developed by the UK company GW Pharmaceuticals Menerba is a botanical drug candidate consisting of 22 herbs that have been used historically in traditional Chinese medicine that act as a selective estrogen receptor modulator. As of 2015 the FDA had approved Bionovo's chemical manufacturing and controls and Menerba was in a Phase III clinical trial as a potential treatment to relieve hot flashes associated with menopause.
== Applications == An early application of TRMS was in the observation of flash photolysis process. It took advantage of a time-of-flight mass analyzer. TRMS currently finds applications in the monitoring of organic reactions, formation of reactive intermediates, enzyme-catalyzed reactions, convection, protein folding, extraction, and other chemical and physical processes.
== See also == CHAIN (disambiguation) The Chain (disambiguation) Chain of Ponds (disambiguation) Chain of thought (disambiguation) Chained (disambiguation) Chane (disambiguation) Daisy chain (disambiguation) Serial (disambiguation)
Sources: en.wikipedia.org
== Emerging technologies == Innovation in the food sector may include, for example, new types for raw material processing technology, packaging of products, and new food additives. Applying new solutions may reduce or prevent adverse changes caused by microorganisms, oxidation of food ingredients, and enzymatic and nonenzymatic reactions. Moreover, healthier and more nutritious food may be delivered as well as the food may taste better due to improvements in food composition, including organoleptic changes, and changes in the perception and pleasures from eating food. In the 21st century, emerging technologies such as cellular agriculture, particularly cultured meat, 3D food printing, use of insect protein, plant-based alternatives, vertical farming, food deliveries and blockchain technology are being developed to accelerate the transformation towards sustainable food systems.
Psychotria viridis (Chacruna) – leaves Psychotria carthagenensis (Amyruca) – leaves Diplopterys cabrerana (Chaliponga, Chagropanga, Banisteriopsis rusbyana) – leaves Mimosa tenuiflora (M. hostilis) - root bark Other common admixtures:
=== As a dietary supplement === Montmorency cherry juice is produced as a dietary supplement, and is manufactured as a concentrate and in capsules as a freeze-dried powder. Claims have been made that cherry juice can be helpful for improving sleep for people with insomnia, but there is no good evidence to support these claims.
== Ecology == In its native habitat Vanilla planifolia depends on one or more pollinators. Several species of bee have been proposed including Euglossa species, Eulaema cingulata, Eulaema polychroma, Eulaema meriana, and Melipona beecheii for pollination. However, no definitive observation of pollination is recorded and the size of M. beecheii in particular make it unlikely to be a pollinator of this species of orchid, though unpublished observations suggest that Euglossa (reported as E. viridissima, but this species has historically been confused with other Euglossa species) might be capable of completing pollination. Attempts to document the visitation of V. planifolia in the Yucatán peninsula of Mexico failed to record any visitation by any stingless bees or orchid bees (including Melipona, Eulaema, and Euglossa), leaving the identity of its natural pollinators as yet unresolved. Though the seeds of Vanilla planifolia are very small, they are relatively large for an orchid and are not dispersed by the wind. Instead they spread through the rainforest habitat by many different animals. Male orchid bees in the tribe Euglossini in the genera Euglossa and Eulaema exhibit fragrance-collecting behavior with the fruits. Specific species observed removing seeds as part of this behavior include Euglossa bursigera, Euglossa ignita, Euglossa tridentata, and Eulaema cingulata. Conversely female stingless bees remove the pulp of the fruit in a behavior consistent with nest-building activities. The two species observed distributing V.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.